EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects

Auslin Sam iD, Chao-Hsiang Peng, Kai-Cheng Hsu, Wei-Chun HuangFu iD

Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-21

DOI: 10.2147/dddt.s631685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Auslin Sam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Apoptosis, Flavonols, Ovarian Neoplasms, Protein Serine-Threonine Kinases. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisFlavonolsOvarian NeoplasmsProtein Serine-Threonine KinasesFerroptosisFlavonoidsProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleDyrk KinasesProtein-Tyrosine KinasesDose-Response Relationship, DrugDrug Screening Assays, AntitumorStructure-Activity RelationshipMolecular Docking SimulationCell ProliferationMolecular Structure

Stichwörter der Autor:innen

DYRK1Bapoptosisferroptosisfisetinovarian cancer

Substanzen

fisetinFlavonolsDyrk KinasesProtein-Tyrosine KinasesProtein Serine-Threonine KinasesFlavonoidsProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Ph.D. Program in Innovative Medical Technology Research and Development Industry, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Auslin Sam, Wei-Chun HuangFu

Zitieren

APA

Sam, A., Peng, C. H., Hsu, K. C., & HuangFu, W. C. (2026). Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects. Drug Design, Development and Therapy, Volume 20, 1-21. https://doi.org/10.2147/dddt.s631685

Vancouver

Sam A, Peng CH, Hsu KC, HuangFu WC. Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects. Drug Design, Development and Therapy. 2026;Volume 20:1-21. doi:10.2147/dddt.s631685

BibTeX
@article{Sam2026,
  author = {Sam, Auslin and Peng, Chao-Hsiang and Hsu, Kai-Cheng and HuangFu, Wei-Chun},
  title = {Identification and Biological Evaluation of Fisetin as a Novel DYRK1B Inhibitor in Ovarian Cancer with Apoptotic and Ferroptotic Effects},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--21},
  doi = {10.2147/dddt.s631685}
}
Kostenlos starten →